Biosimilars 101 and Beyond

This CME program is designed to provide health care professionals with an in-depth understanding of the role of biosimilars in the treatment of psoriatic disease, including both psoriasis and psoriatic arthritis. The program will also address practical aspects of integrating biosimilars into clinical practice, such as patient education, switching protocols, and overcoming barriers to adoption. This program is CME accredited for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.